BIONTECH SE SPON. ADRS 1
Commented by André Will-Laudien on January 3rd, 2023 | 07:26 CET
New COVID outbreak in China: BioNTech, Cardiol Therapeutics, CureVac and Valneva shares in focus again in 2023
The next COVID wave is rolling towards Europe. Representatives of the EU states therefore want to discuss a unified approach on Wednesday due to the latest development in China. The main issue is how to deal with entrants from China. A spokeswoman for the Federal Ministry of Health in Berlin said that the situation is being closely monitored and that the EU partners are also being consulted. At French airports, arrivals from China are already generally tested for the virus. Italy and Spain have also reacted with corresponding regulations. The German government sees no reason to do so so far. Is Germany too slow again, or is prudence the order of the day?
Read
Commented by Stefan Feulner on December 30th, 2022 | 17:52 CET
BioNTech, Defence Therapeutics, Pfizer - The cards are being reshuffled
The Corona pandemic is seemingly coming to an end after almost three long years. The return to normality, now in China and the rest of the world, is a relief for society and the economy. In contrast, vaccine manufacturers are losing a billion-dollar business that is difficult to compensate for with products in other areas of application. Nevertheless, the stock market valuations of the vaccine producers continue to be exorbitantly high, as does their drop in value.
Read
Commented by Fabian Lorenz on December 28th, 2022 | 08:05 CET
Outperformer stocks in 2023? BioNTech, Steinhoff, Saturn Oil + Gas, K+S
Will energy stocks continue to be outperformers in 2023? In any case, in 2022, MSCI World Energy clearly outperformed MSCI World. In the case of individual stocks, Shell, for example, has gained over 45% in the current year. Jefferies recommends the stock as a buy with a target price of GPX 3100 (pence). Warren Buffett has also invested billions in the oil sector in 2022. Chevron and Occidental Petroleum are among Berkshire Hathaway's seven largest holdings. Energy, after all, is likely to be in demand in 2023. Those looking to bet on a laggard should look at Saturn Oil & Gas. The Canadian oil producer faces a milestone in 2023, and analysts see over 200% upside potential. BioNTech enters the new year with solid newsflow. And what is Steinhoff doing after the horror news?
Read
Commented by Juliane Zielonka on December 23rd, 2022 | 08:00 CET
BioNxt Solutions, MorphoSys, BioNTech - Innovations and scaling potential for the portfolio
Around the world, patients are used to swallowing medicines in pill form. Sales of oral, fixed-dose drugs alone accounted for a whopping 23.8% of the global pharmaceutical drug delivery market in 2021. That is reason enough for Canadian biotech company BioNxt Solutions to further expand its strategic pole position. BioNxt Solutions secures further rights to a unique platform technology in this segment. Caution is currently the order of the day for MorphoSys. Analysts downgrade the target price from EUR 16 to EUR 12 after a disappointing Q3. BioNTech, on the other hand, can expand its dominance. The Mainz-based company is scaling up in the Asia-Pacific region with new production sites.
Read
Commented by Fabian Lorenz on December 21st, 2022 | 08:48 CET
BASF, BioNTech, Cardiol Therapeutics: Stocks for 2023?
Is there a 400% upside potential in 2023? At the end of a challenging 2022 stock market year, we are looking ahead to the new year. Which share is worth buying, and which is better left alone? In the case of BASF, the high dividend yield is one of the attractions. The latest company news shows that the chemical group is also involved in the mega market of electromobility. But the dependence on gas supplies is causing uncertainty, and an analyst has renewed a sell recommendation for BASF shares. BioNTech, on the other hand, is looking good, even if the chart picture has recently clouded over. The development pipeline is full, capacities - especially in Asia - are being expanded, and analysts are also more courageous again. Investors also need a little courage and, above all, patience with Cardiol Therapeutics. They could soon be rewarded. The cash position of the biotech pearl is almost equal to the market capitalization, the main product is already in the Phase 2 pilot study, and analysts see massive upside potential.
Read
Commented by Fabian Lorenz on December 19th, 2022 | 13:57 CET
BioNTech top, Morphosys flop and Defence Therapeutics takeover candidate?
Biotech shares are volatile. Investors were reminded of this again just last week. Moderna shares initially rose by almost 30%, only to fall back by around 10% towards the weekend. But overall, the mood in the biotech segment was positive. Moderna reported positive study results on a combination therapy of a Moderna cancer vaccine and the tumor drug pembrolizumab from Merck & Co. At BioNTech, two buy recommendations and the expansion in Asia created a good mood. This mood has also prevailed at Defence Therapeutics for several weeks. The Canadians reported positive study results against tumors, and their Accum technology delivers what it promises, in which case mRNA specialists such as Moderna, BioNTech and Co. should be interested in a cooperation or even acquisition. In contrast, Morphosys slides to a new multi-year low.
Read
Commented by Fabian Lorenz on December 14th, 2022 | 12:02 CET
Bayer, BioNTech, Auxico Resources: 200% price gain possible?
With lower than expected inflation in the US, the year-end rally has picked up speed. Could the recession be off after all, or at least short-lived? This would likely boost the stock market in the coming year as well. Today we look at three stocks with potential that benefit from global trends and less from developments in Germany. In the case of Bayer, Bernstein Research has outed itself as a super bull. The global agricultural business should continue to run strong. Auxico Resources is positioning itself as a trader of rare earths and critical raw materials. Revenues are expected to jump significantly in the coming year, and analysts say the stock could triple. BioNTech could finally break out of the sideways trend it has been in since early 2022. The new combination vaccine and the cancer pipeline give hope.
Read
Commented by Stefan Feulner on December 13th, 2022 | 10:43 CET
Rheinmetall, Aspermont, BioNTech - Strong momentum
With its many drastic events, the turbulent stock market year 2022 is drawing to a close. With the Ukraine war, the change in monetary policy by central banks and rampant inflation, the year was characterized by strong uncertainty and high volatility, and it is almost certain to continue in the coming year. Nevertheless, the favourites are emerging more and more clearly from various sectors that should outperform the broad market in the months ahead.
Read
Commented by Armin Schulz on December 12th, 2022 | 10:20 CET
BioNTech, va-Q-tec, Cardiol Therapeutics, Ambrx Biopharma - Biotech second-line stocks explode
For investors in biotech stocks, 2022 was often a year to forget. After the Corona hype, the market clouded over significantly, in part due to rising interest rates. December is the time of year when investors can make adjustments to their portfolio, thereby reducing their tax burden for the year ahead. This year is no exception, yet three stocks shot up last Friday. That is unusual during tax loss season. We look at the three high flyers and BioNTech, a big player in the biotech sector.
Read
Commented by Nico Popp on December 8th, 2022 | 09:05 CET
Where the money is made: BioNTech, Novavax, Cardiol Therapeutics
While the first federal states in Germany are lifting the mask requirement on public transport, suppliers of vaccines and medicines are far from going back to normal. Even corona vaccines are in high demand. While there is a shortage of antipyretics and medication in this country, especially for children, innovative companies are already addressing the next challenges. We explain where investors can make money.
Read